Table 1 Correlations between metformin use and clinic pathological characteristics in diabetic NSCLC patients (n = 255)
From: Prognostic value of metformin for non-small cell lung cancer patients with diabetes
All (n = 255) | Metformin (n = 150, 58.8%) | Non-metformin (n = 105, 41.2%) | p value | |
|---|---|---|---|---|
Age (years) | ||||
≥ 65 | 117 (45.9%) | 63 (42.0%) | 54 (51.4%) | 0.565 |
< 65 | 138 (54.1%) | 87 (58.0%) | 51 (48.6%) | |
Gender (%) | ||||
Male | 204 (80.0%) | 108 (72.0%) | 96 (91.4%) | 0.053 |
Female | 51 (20.0%) | 42 (28.0%) | 9 (8.6%) | |
Smoking history | ||||
No | 21 (8.2%) | 12 (8.0%) | 9 (8.6%) | 0.612 |
Yes | 234 (91.8%) | 138 (92.0%) | 96 (91.4%) | |
BA1c (mmol/mol) | 51.7 ± 14.5 | 53.3 ± 18.65 | 0.238 | |
Histology | ||||
Squamous | 51 (20.0%) | 24 (16.0%) | 27 (15.7%) | 0.357 |
Non-squamous | 204 (80.0%) | 126 (84.0%) | 78 (74.3%) | |
Tumor location | 0.189 | |||
Left | 114 (54.1%) | 63 (42.0%) | 51 (48.6%) | |
Right | 141 (55.3%) | 87 (58.0%) | 54 (51.4%) | |
Stage | ||||
I | 69 (27.1%) | 42 (28.0%) | 27 (25.7%) | 0.541 |
II | 144 (56.5%) | 87 (58.0%) | 57 (54.3%) | |
III | 42 (16.4%) | 21 (14.0%) | 21 (20.0%) | |
Chemotherapy | ||||
No | 72 (28.2%) | 45 (30.0%) | 27 (25.7%) | 0.200 |
Yes | 183 (72.8%) | 105 (70.0%) | 78 (75.3%) | |
Thoracic irradiation | ||||
No | 213 (83.6%) | 126 (84.0%) | 87 (82.9%) | 0.554 |
Yes | 42 (16.4%) | 24 (16.0%) | 18 (17.1%) | |
Tumor recurrence | ||||
No | 165 (64.7%) | 111 (74.0%) | 54 (51.5%) | 0.015 |
Yes | 90 (35.3%) | 39 (26.0%) | 51 (48.5%) | |